|
시장보고서
상품코드
2067596
인슐린 아스파트 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Insulin Aspart Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
인슐린 아스파트 시장 개요
세계의 인슐린 아스파트 시장 규모는 2025년에 35억 2,000만 달러로 추계되며, 2033년까지 50억 1,985만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 4.60%로 성장할 것으로 전망되고 있습니다.
이 시장은 전 세계 당뇨병 부담의 증가에 힘입어 꾸준한 성장을 달성하고 있습니다. 특히 신흥 경제국에서는 생활 습관의 변화와 도시화가 진행됨에 따라 질병 유병률이 급속히 증가하고 있습니다.
비만 증가, 운동 부족, 고령화 진행이 인슐린 의존율 상승에 크게 기여하고 있습니다. 또한 선별 검사 프로그램의 개선과 조기 진단 노력에 힘입어 인슐린 치료가 필요한 환자층이 확대되고 있습니다. 정부 주도의 인식 제고 캠페인과 의료제도 개혁 또한 치료의 보급을 더욱 지원하고 있습니다. 장기적인 합병증을 예방하기 위한 효과적인 혈당 관리에 대한 관심이 높아지고 있는 점도 수요를 끌어올리고 있습니다. 그 결과, 인슐린 아스파트와 같은 속효성 인슐린 아날로그가 치료 옵션으로 점점 더 선호되고 있습니다.
인슐린 펜, 펌프, 스마트 투여 시스템 등 인슐린 투여 기술의 지속적인 발전이 시장 성장을 더욱 촉진하고 있습니다. 이러한 혁신은 환자의 편의성, 투여의 정확성, 치료 순응도를 높여, 결과적으로 임상적 결과의 개선으로 이어지고 있습니다. 연속 혈당 모니터링(CGM) 시스템이나 네트워크 접속형 인슐린 기기 같은 디지털 헬스 툴의 통합은 실시간 당뇨병 관리를 한층 더 지원하고 있습니다. 각 제약사들도 가격에 민감한 시장에서 시장 접근성을 확대하기 위해 바이오시밀러 및 비용 대비 효과가 높은 제제의 개발에 주력하고 있습니다. 의료비 증가와 당뇨병 치료에 대한 보험 적용 범위 확대에 따라 첨단 인슐린 요법에 대한 접근성이 높아지고 있습니다. 이러한 요인들이 복합적으로 작용하여, 인슐린 아스파트를 기반으로 한 치료법의 시장 침투를 강력하게 촉진하고 있습니다.
또한 시장은 규제 당국의 긍정적인 승인 및 다양한 환자 집단에서의 제품 적응증 확대라는 혜택을 누리고 있습니다. 주요 업계 기업의 전략적 제휴, 파트너십 및 신제품 출시는 전 세계 유통망을 강화하고 시장내 입지를 공고히 하고 있습니다. 또한 환자 한 명 한 명에게 맞춘 인슐린 요법을 통해 치료 성과를 높이는 ‘맞춤형 의료’로의 전환도 진행되고 있습니다. 병원 및 재택 의료 현장에서의 수요가 증가함에 따라 제품 이용이 더욱 확대되고 있습니다. 또한 연구개발에 대한 투자 확대가 제제 개선 및 차세대 인슐린 제품 개발을 촉진하고 있습니다. 이러한 요인들이 복합적으로 작용함에 따라 전 세계 인슐린 아스파트 시장에서 장기적인 성장세가 지속될 것으로 예상됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 인슐린 아스파트 시장 : 변수, 동향, 범위
제4장 인슐린 아스파트 시장 : 제품별 비즈니스 분석
제5장 인슐린 아스파트 시장 : 용도별 비즈니스 분석
제6장 인슐린 아스파트 시장 : 유통 채널별 비즈니스 분석
제7장 인슐린 아스파트 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSA 26.06.29Insulin Aspart Market Summary
The global insulin aspart market size was estimated at USD 3,520.00 million in 2025 and is projected to reach USD 5,019.85 million by 2033, growing at a CAGR of 4.60% from 2026 to 2033. The market is experiencing steady growth driven by the increasing global burden of Diabetes Mellitus, particularly in emerging economies where lifestyle changes and urbanization are accelerating disease prevalence.
Rising incidences of obesity, sedentary habits, and aging populations are significantly contributing to higher insulin dependency rates. In addition, improved screening programs and early diagnosis initiatives are expanding the patient pool requiring insulin therapy. Government-led awareness campaigns and healthcare reforms are further supporting the adoption of treatment. The growing emphasis on effective glycemic control to prevent long-term complications is also strengthening demand. As a result, rapid-acting insulin analogs such as Insulin Aspart are increasingly preferred therapeutic options.
The continuous advancement in insulin delivery technologies, including insulin pens, pumps, and smart delivery systems, is further fueling the growth of the market. These innovations enhance patient convenience, dosing accuracy, and adherence to therapy, thereby improving clinical outcomes. The integration of digital health tools, such as continuous glucose monitoring (CGM) systems and connected insulin devices, is further supporting real-time diabetes management. Pharmaceutical companies are also focusing on developing biosimilars and cost-effective formulations to expand accessibility across price-sensitive markets. Increasing healthcare expenditure and insurance coverage for diabetes care are enabling broader access to advanced insulin therapies. Collectively, these factors are fostering strong market penetration of insulin aspart-based treatments.
Furthermore, the market is benefiting from favorable regulatory approvals and expanding product applications across different patient populations. Strategic collaborations, partnerships, and product launches by key industry players are enhancing global distribution networks and strengthening market presence. There is also a growing shift toward personalized medicine, where tailored insulin regimens improve patient-specific outcomes. Rising demand in hospital and homecare settings is further boosting product utilization. In addition, increased investments in research and development are driving formulation improvements and the development of next-generation insulin products. These combined dynamics are expected to sustain long-term growth momentum for the insulin aspart market worldwide.
Global Insulin Aspart Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global insulin aspart market report based on product, application, distribution channel, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Branded
- Biosimilar
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government / Institutional Tenders
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Insulin Aspart Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Insulin Aspart Market: Product Business Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Branded
- 4.4.1. Branded Market, 2021 - 2033 (USD Million)
- 4.5. Biosimilar
- 4.5.1. Biosimilar Market, 2021 - 2033 (USD Million)
Chapter 5. Insulin Aspart Market: Application Business Analysis
- 5.1. Application Market Share, 2025 & 2033
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Type 1 Diabetes-
- 5.4.1. Type 1 Diabetes Market, 2021 - 2033 (USD Million)
- 5.5. Type 2 Diabetes-
- 5.5.1. Type 2 Diabetes Market, 2021 - 2033 (USD Million)
- 5.6. Gestational Diabetes-
- 5.6.1. Gestational Diabetes Market, 2021 - 2033 (USD Million)
Chapter 6. Insulin Aspart Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2025 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
- 6.7. Government / Institutional Tenders
- 6.7.1. Government / Institutional Tenders Market, 2021 - 2033 (USD Million)
Chapter 7. Insulin Aspart Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Insulin Aspart Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Target Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Target Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Target Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Target Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Target Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Insulin Aspart Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Novo Nordisk
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Sanofi
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Biocon
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Wockhardt
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Tonghua Dongbao Pharmaceutical Co., Ltd.
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Gan & Lee Pharmaceuticals
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Julphar (Gulf Pharmaceutical Industries)
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Geropharm
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. United Laboratories International Holdings Limited
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Sedico Pharmaceutical Company
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.1. Novo Nordisk
